• Mehul Malhotra
    Mehul Malhotra
    • Get shareable images
    • Copy Link

    • Share on Facebook
    • Share on X
    • Share on LinkedIn
    • Share on BlueSky
    • Share on Threads
    • Share on Reddit
Mehul Malhotra logo
    • Change photo
  • Delete photo

Mehul Malhotra

  • 0 Followers

  • 2 Following

  • The Rising Horizon of the Vagus Nerve Stimulator MarketThe Rising Horizon of the Vagus Nerve Stimulator Market

    The Rising Horizon of the Vagus Nerve Stimulator Market

    The intersection of neuroscience and medical technology has given rise to one of the most transformative therapeutic innovations of recent decades. The vagus nerve stimulator a small implantable or wearable device that delivers electrical impulses to the body's longest cranial nerve is redefining how physicians approach conditions that have long resisted conventional pharmacological treatment. From drug-resistant epilepsy to treatment-resistant depression, the scope of vagus nerve stimulation VNS continues to expand, attracting significant attention from clinicians, researchers, and the MedTech industry alike.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Advantages in Drug CommercializationTop 10 HEOR Advantages in Drug Commercialization

    Top 10 HEOR Advantages in Drug Commercialization

    Health Economics and Outcomes Research (HEOR) plays a pivotal role in guiding healthcare decision-making worldwide. As payers, regulators, and health systems demand greater evidence of value, HEOR models have become indispensable tools in Health Technology Assessment (HTA). Whether you're evaluating cost-effectiveness, budget impact, or quality-adjusted life years (QALYs), choosing the right HEOR modeling partner can make or break your market access strategy.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Companies Leveraging Real-World Data (RWD)Top 10 HEOR Companies Leveraging Real-World Data (RWD)

    Top 10 HEOR Companies Leveraging Real-World Data (RWD)

    In today's rapidly evolving healthcare landscape, Health Economics and Outcomes Research (HEOR) has become a critical pillar in demonstrating the value of therapies beyond clinical trials. As payers, regulators, and healthcare systems demand stronger evidence, companies leveraging Real-World Data (RWD) are gaining a decisive edge. From claims databases to electronic health records (EHRs), RWD is reshaping how market access decisions are made.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Companies in Immunology and Autoimmune DiseasesTop 10 HEOR Companies in Immunology and Autoimmune Diseases

    Top 10 HEOR Companies in Immunology and Autoimmune Diseases

    The growing complexity of immunology and autoimmune diseases ranging from rheumatoid arthritis and lupus to multiple sclerosis and psoriasis has made Health Economics and Outcomes Research (HEOR) indispensable. As biopharmaceutical companies seek market access and payer approval for high-cost therapies, HEOR evidence forms the backbone of value demonstration strategies. Below is a curated list of the Top 10 HEOR Companies in Immunology and Autoimmune Diseases that are shaping the landscape of evidence generation and health technology assessment (HTA).

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Companies in Neurology ResearchTop 10 HEOR Companies in Neurology Research

    Top 10 HEOR Companies in Neurology Research

    Neurological disorders from Alzheimer's disease and multiple sclerosis to Parkinson's and epilepsy represent one of the most complex and costly therapeutic areas in global healthcare. As the burden of neurological conditions continues to rise, pharma and biotech companies increasingly rely on Health Economics and Outcomes Research (HEOR) to demonstrate the real-world value of their therapies, support reimbursement decisions, and guide clinical strategy.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Companies for Cardiovascular Disease StudiesTop 10 HEOR Companies for Cardiovascular Disease Studies

    Top 10 HEOR Companies for Cardiovascular Disease Studies

    Cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for nearly 18 million deaths annually. As the burden of heart disease, stroke, and related conditions continues to rise, the demand for robust Health Economics and Outcomes Research (HEOR) has never been greater. Pharmaceutical companies, medical device manufacturers, and health systems increasingly rely on specialized HEOR firms to generate real-world evidence, cost-effectiveness models, and outcomes data that inform market access, reimbursement, and clinical decisions.

    Mehul Malhotra
    Mehul Malhotra
  • Crovalimab: Transforming the Treatment Landscape for Paroxysmal Nocturnal HemoglobinuriaCrovalimab: Transforming the Treatment Landscape for Paroxysmal Nocturnal Hemoglobinuria

    Crovalimab: Transforming the Treatment Landscape for Paroxysmal Nocturnal Hemoglobinuria

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder characterized by complement-mediated destruction of red blood cells, leading to hemolysis, thrombosis, and bone marrow failure. For years, patients relied on intravenous infusions administered every two weeks, a regimen that imposed significant physical and logistical burdens. That treatment paradigm is now shifting dramatically, thanks to Crovalimab, a next-generation complement inhibitor developed by Chugai Pharmaceutical in collaboration with Roche.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Approaches to Support Regulatory SubmissionsTop 10 HEOR Approaches to Support Regulatory Submissions

    Top 10 HEOR Approaches to Support Regulatory Submissions

    Health Economics and Outcomes Research (HEOR) has become a cornerstone of strategic decision-making in the pharmaceutical and life sciences sector. As payer scrutiny intensifies and market access grows increasingly complex, organizations must leverage HEOR analysis companies to stay ahead of competitors. From economic modeling to real-world evidence, the insights generated through rigorous HEOR frameworks can directly influence product positioning, pricing strategies, and launch success. Here are the top 10 HEOR insights that are shaping competitive intelligence today.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Insights for Competitive IntelligenceTop 10 HEOR Insights for Competitive Intelligence

    Top 10 HEOR Insights for Competitive Intelligence

    Health Economics and Outcomes Research (HEOR) has become a cornerstone of strategic decision-making in the pharmaceutical and life sciences sector. As payer scrutiny intensifies and market access grows increasingly complex, organizations must leverage HEOR analysis companies to stay ahead of competitors. From economic modeling to real-world evidence, the insights generated through rigorous HEOR frameworks can directly influence product positioning, pricing strategies, and launch success. Here are the top 10 HEOR insights that are shaping competitive intelligence today.

    Mehul Malhotra
    Mehul Malhotra
  • Top 10 HEOR Data Sources for Robust AnalysisTop 10 HEOR Data Sources for Robust Analysis

    Top 10 HEOR Data Sources for Robust Analysis

    Top 10 HEOR Data Sources for Robust Analysis

    Mehul Malhotra
    Mehul Malhotra
  • Evidence-Based Insights: Reshaping Modern Healthcare Value AssessmentEvidence-Based Insights: Reshaping Modern Healthcare Value Assessment

    Evidence-Based Insights: Reshaping Modern Healthcare Value Assessment

    The contemporary healthcare ecosystem demands more than traditional clinical efficacy data when evaluating medical interventions. As global health systems face mounting financial pressures alongside an explosion of therapeutic options, demonstrating tangible value has become essential. Pharmacoeconomic analysis provides the quantitative framework needed to compare interventions, examining both costs and benefits to determine whether innovative therapies deliver meaningful advantages over established treatment protocols.

    Mehul Malhotra
    Mehul Malhotra
  • Why HEOR Analysis Is the Cornerstone of Modern Healthcare Decision-MakingWhy HEOR Analysis Is the Cornerstone of Modern Healthcare Decision-Making

    Why HEOR Analysis Is the Cornerstone of Modern Healthcare Decision-Making

    In an era where every healthcare dollar must be justified and every treatment decision scrutinized, the discipline of HEOR analysis — Health Economics and Outcomes Research — has emerged as an indispensable tool for pharmaceutical companies, payers, and regulators alike. Far beyond traditional clinical trials, HEOR bridges the gap between what a treatment can do under controlled conditions and what it actually delivers for real-world patients, populations, and healthcare systems.

    Mehul Malhotra
    Mehul Malhotra
  • TEZSPIRE: Charting a New Course in Severe Asthma and BeyondTEZSPIRE: Charting a New Course in Severe Asthma and Beyond

    TEZSPIRE: Charting a New Course in Severe Asthma and Beyond

    TEZSPIRE: Charting a New Course in Severe Asthma and Beyond

    Mehul Malhotra
    Mehul Malhotra
  • MNKD-101: Clofazimine Inhalation Suspension and the Future of NTM Lung Disease TreatmentMNKD-101: Clofazimine Inhalation Suspension and the Future of NTM Lung Disease Treatment

    MNKD-101: Clofazimine Inhalation Suspension and the Future of NTM Lung Disease Treatment

    Nontuberculous mycobacterial (NTM) lung disease has long been one of the most underserved areas in pulmonary medicine. As awareness grows and patient populations expand globally, the pharmaceutical industry is rising to meet the challenge. At the forefront of this effort was MNKD-101  an investigational nebulized formulation of clofazimine developed by MannKind Corporation, designed to deliver targeted pulmonary therapy to patients battling Mycobacterium avium complex (MAC) infections.

    Mehul Malhotra
    Mehul Malhotra
  • VOXZOGO: Transforming Achondroplasia Treatment Market Outlook, Pricing, and Pipeline to 2034VOXZOGO: Transforming Achondroplasia Treatment Market Outlook, Pricing, and Pipeline to 2034

    VOXZOGO: Transforming Achondroplasia Treatment Market Outlook, Pricing, and Pipeline to 2034

    The rare disease therapeutics landscape has witnessed a landmark shift with the emergence of VOXZOGO (vosoritide), BioMarin Pharmaceutical's groundbreaking C-type natriuretic peptide (CNP) analog. As the first and only approved pharmacological therapy for achondroplasia the most common form of short-limbed dwarfism this drug has redefined clinical expectations for children living with this rare skeletal dysplasia. With regulatory approvals secured across multiple geographies and a robust commercial trajectory, the drug is now a focal point for investors, healthcare providers, and market analysts tracking rare disease innovation.

    Mehul Malhotra
    Mehul Malhotra
  • Understanding the Nitisinone Market: Growth Drivers, Forecast, and Clinical ImpactUnderstanding the Nitisinone Market: Growth Drivers, Forecast, and Clinical Impact

    Understanding the Nitisinone Market: Growth Drivers, Forecast, and Clinical Impact

    The pharmaceutical landscape for rare metabolic disorders continues to evolve, with Nitisinone emerging drug as a cornerstone therapeutic option for patients suffering from hereditary tyrosinemia type 1 (HT-1) and alkaptonuria (AKU). As global healthcare systems increasingly prioritize early diagnosis and intervention, the market for this life-altering medication continues to expand significantly across major pharmaceutical markets.

    Mehul Malhotra
    Mehul Malhotra
  • Migalastat Market Growth: Key Insights into Fabry Disease Treatment EvolutionMigalastat Market Growth: Key Insights into Fabry Disease Treatment Evolution

    Migalastat Market Growth: Key Insights into Fabry Disease Treatment Evolution

    The pharmaceutical landscape for rare genetic disorders continues to evolve, with precision medicine approaches gaining significant traction. Migalastat has emerged as a revolutionary treatment option for Fabry disease patients with amenable mutations, fundamentally changing how clinicians approach managing this debilitating lysosomal storage disorder. Recent Migalastat Sales Forecast data reveals robust growth potential across major pharmaceutical markets through 2034.

    Mehul Malhotra
    Mehul Malhotra
  • Understanding Eculizumab: Market Growth, Trends, and Future OutlookUnderstanding Eculizumab: Market Growth, Trends, and Future Outlook

    Understanding Eculizumab: Market Growth, Trends, and Future Outlook

    The pharmaceutical landscape for rare immunological disorders is rapidly evolving, with Eculizumab Sales Forecast data showing remarkable momentum through 2034. As a complement C5 inhibitor, eculizumab (marketed as Soliris) has established itself as a cornerstone therapy in the treatment of life-threatening rare diseases. The market is experiencing significant transformation driven by indication expansion, biosimilar launches, and increased diagnostic awareness globally.

    Mehul Malhotra
    Mehul Malhotra
  • Revolutionary Gene Therapy: Understanding HEMGENIX’s Market Growth and Clinical ImpactRevolutionary Gene Therapy: Understanding HEMGENIX’s Market Growth and Clinical Impact

    Revolutionary Gene Therapy: Understanding HEMGENIX’s Market Growth and Clinical Impact

    HEMGENIX (Etranacogene dezaparvovec) represents a paradigm shift in the treatment of hemophilia B, standing as the first and only FDA and EMA-authorized gene therapy for adults with severe and moderately severe hemophilia B. This groundbreaking therapeutic intervention has transformed the hemophilia treatment landscape, offering patients a one-time durable treatment alternative to chronic factor replacement therapy. As the pharmaceutical and healthcare sectors continue to monitor this innovative therapy, understanding its commercial trajectory and market dynamics becomes increasingly important for stakeholders, investors, and healthcare professionals.

    Mehul Malhotra
    Mehul Malhotra
  • Understanding SPINRAZA: A Breakthrough Treatment for Spinal Muscular AtrophyUnderstanding SPINRAZA: A Breakthrough Treatment for Spinal Muscular Atrophy

    Understanding SPINRAZA: A Breakthrough Treatment for Spinal Muscular Atrophy

    SPINRAZA is a groundbreaking antisense oligonucleotide medication designed to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects motor neurons and causes progressive muscle weakness. Approved by the FDA in December 2016, SPINRAZA has transformed the treatment landscape for SMA patients worldwide. For comprehensive insights into this revolutionary drug, explore the detailed SPINRAZA Insight report that provides extensive market analysis and clinical data.

    Mehul Malhotra
    Mehul Malhotra